Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

ROCKVILLE, Md., Oct  27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed Phase Ia in the ongoing safety trial to test its neuroregenerative small molecule drug, NSI-189, in the treatment of major depressive disorder (MDD).  Phase Ia tested the drug in healthy volunteers for safety and tolerability. Phase Ib, which the company expects to commence later this year, will test the safety and tolerability of NSI-189 in depressed patients.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD and other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).

"We are extremely pleased the trial has progressed so smoothly," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "We didn't see any drug-related adverse effects in this set of patients. We are eager to move to the next phase of this safety trial, where we will be testing NSI-189 in patients who suffer from major depressive disorder."

About the Trial

This Phase Ia trial tested single ascending doses of NSI-189 in healthy patients. Standard safety endpoints were monitored.  All doses were well tolerated and there were no drug-related serious adverse events.  The trial will commence to the Ib phase, testing the safety of escalating doses of daily administration for 28 days in depressed patients. The entire Phase I trial is expected to be approximately one year in duration.

About NSI-189

NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
(Date:4/18/2014)... Research Institute at Virginia Mason (BRI) recently received a ... metastatic breast cancer reduces both the growth of primary ... have found in models of the disease that blocking ... percent and can keep the tumor from metastasizing or ... comes from the National Cancer Institute of the National ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2
... , ... leaders Earn Prestigious Parallels Partner Awards for innovation, branding, inspiration and growth at the ... ... , today announced the winners of its inaugural Partner Awards at the Parallels Summit ...
... , , ... ... ... ...
... a cruel, hereditary condition that leads to severe physical and ... are no treatments to slow down or stop it. ... not show symptoms until late in life. In a ... Stephen Ferguson and Fabiola Ribeiro of Robarts Research Institute at ...
... ... a business process consultant, life coach and self improvement veteran of more ... coaches to market their services, as well as an Ask-a-Coach corner where ... of information where coaches, clients and visitors may freely interact. ...
... ... ... ... ...
... proteins in premalignant oral lesions may predict oral ... SIBLINGs, or Small Integrin-Binding Ligand N-linked Glycoproteins, ... mineralize bone but can also spread cancer. SIBLINGs ... colon and prostate. "Several years ago we ...
Cached Medicine News:Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 2Health News:Winners are Grinners at the Inaugural Parallels Partner Awards 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 2Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 3Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 4Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 5Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 6Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 7Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 8Health News:Jiffy Lube(R) Well On Its Way to Raising Another $1 Million to Fight Heart Disease 9Health News:Protecting the brain from a deadly genetic disease 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 2Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 3Health News:Improvement Now Made Easier With Self-Improvement-Life-Coach.com 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 2Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 3Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 4Health News:ChildCare Education Institute Supports the First Lady's Efforts to Reduce Childhood Obesity 5Health News:SIBLING proteins may predict oral cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: